851305-26-5

LJ001 is a broad-spectrum and orally active antiviral agent. LJ001 exerts antiviral activities by binding to viral membranes. LJ001 inhibits TGEV and PDCoV infection. LJ001 decreases TGEV N and PDCoV N-protein expression[1][2].

[1] Zhang Y, et al. Rhodanine derivative LJ001 inhibits TGEV and PDCoV replication in vitro. Virus Res. 2020 Nov;289:198167. DOI:10.1016/j.virusres.2020.198167
[2] Wolf MC, et al. A broad-spectrum antiviral targeting entry of enveloped viruses. Proc Natl Acad Sci U S A. 2010 Feb 16;107(7):3157-62. DOI:10.1073/pnas.0909587107